Treatment of Sjögren Syndrome with Arthritis and Active Systemic Disease
This protocol applies to patients with Sjögren syndrome who present with arthritis — objective inflammation of one or more joints — alongside active systemic disease defined by a clinESSDAI score of 1 or higher.
Clinical Scenario
Arthritis in this setting is confirmed by objective signs — heat, redness, and swelling on physical examination of the affected joint — with ultrasound considered when clinical findings are equivocal. Systemic disease activity is quantified using the ESSDAI; a clinESSDAI ≥1 signals the threshold for active treatment in this population.
Treatment Approach (partial)
Glucocorticoid therapy is the central pharmacological intervention. The specific route of administration and intensity of the regimen differ according to whether the presentation is moderate or severe.
Complete dosing strategy, induction approach, tapering guidance, and maintenance targets are detailed in the full protocol below.
▶
Treatment goal: A reduction of at least 3 points in the global ESSDAI score, indicating meaningful control of systemic disease activity.
References
DOI: 10.1136/annrheumdis-2019-216114
- Arthritis is clinically diagnosed on the basis of objective inflammation of >=1 joints (heat, redness and swelling in the physical examination of the affected joint) supported by ultrasound studies when in doubt, and the ESSDAI score classifies the severity of arthritis according to the number of joints involved (moderate <5 joints, high >5).
- GCs should be used at the minimum dose and length of time necessary to control active systemic disease, administering pulses of methylprednisolone followed by doses of 0.5 mg/kg/d or lower as induction therapy in severe presentations, and doses <0.5 mg/kg/d in moderate/less-severe presentations, with a final target of withdrawing GCs in inactive patients as soon as possible or at least trying to target a maintenance dose of 5 mg/daily or less with the aid of GC-sparing immunosuppressive agents.
- GC (recommended dose in mg/kg/day); short-term course whenever possible; consider methylprednisolone pulses in severe cases.
- With respect to the definition of the therapeutic response in systemic SjS, the TF recommends using a reduction of >=3 points in the global ESSDAI score.
View source ↗